Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent & Trademark Office (USPTO) has granted Achillion Pharmaceuticals US Patent No. 7,906,619, covering composition-of-matter and method of use claims for hepatitis C virus (HCV) drug ACH-1625 and structurally related compounds.
Subscribe to our email newsletter
ACH-1625 is Achillion‘s phase 2 protease inhibitor to treat hepatitis C virus (HCV) infection.
The new patent, entitled ‘4-amino-4-oxobutanoyl peptides as inhibitors of viral replication,’ provides a patent term until 2029.
Achillion president and CEO Michael Kishbauch said the key patent grant provides a cornerstone for Achillion’s intellectual property portfolio for ACH-1625 and a number of structurally related compounds, molecules that were discovered and synthesized here by Achillion’s discovery team.
"We believe this strengthening of our patent estate, combined with our expected upcoming pipeline milestones, including 4-week rapid viral response, or RVR, results from an ongoing phase 2 clinical trial of ACH-1625, and the advancement of ACH-2684 and ACH-2928 into phase 1 clinical development during the first half of 2011, will make this a transformational year for Achillion," Kishbauch said.